Lasers in Medical Science

, Volume 34, Issue 7, pp 1509–1511 | Cite as

In response to the FDA warning about the use of photomedicine in gynecology

  • Juan José Escribano
  • Pablo González-Isaza
  • Konstantinos Tserotas
  • Stavros Athanasiou
  • Nicola Zerbinati
  • Gustavo Leibaschoff
  • Stefano Salvatore
  • Rafael Sánchez-BorregoEmail author
Letter to the Editor


To alert patients and health care providers about the use of energy-based devices to perform a vaginal “rejuvenation,” cosmetic vaginal procedures, or nonsurgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function, the US Food and Drug Administration (FDA) has issued a warning about the effectiveness and safety of such devices. We agree with the FDA that certain devices (laser, radiofrequency, etc.) have been marketed inappropriately for uses that are outside of their cleared or approved intended uses. We want to position ourselves in the strict training of professionals so that the indications and techniques are used in the best possible way, knowing that, similar to any medical or surgical technique, the side effects can appear in the short and long term, and should be recognized and remedied.


FDA safety communication Energy-based devices Vaginal ‘rejuvenation’ Vaginal cosmetic procedures 


Authors’ contribution

All authors contributed equally to writing this editorial.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    FDA Warns Against Use of Energy-Based Devices to Perform Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures: FDA safety communication. Date Issued: July 30, 2018Google Scholar
  2. 2.
    The American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Administration clearance: position statement. May 2016Google Scholar
  3. 3.
    Portman DJ, Gass ML (2014) Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med 11(12):2865–2872CrossRefGoogle Scholar
  4. 4.
    Bachmann G, Santen RJ (2018) Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). UpToDateGoogle Scholar
  5. 5.
    Salvatore S, Athanasiou S, Candiani M (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27(6):504–508Google Scholar
  6. 6.
    González-Isaza P, Sánchez-Borrego R, Escribano JJ, Zerbinati N, Tserotas K, Leibaschoff G (2018 June) Letters To the editor. Menopause 25(6):710CrossRefGoogle Scholar
  7. 7.
    Krychman M, Rowan CG, Allan BB, Durbin S, Yacoubian A, Wilkerson D (2018) Effect of single-session, cryogen-cooled monopolar radiofrequency therapy on sexual function in women with vaginal laxity: the VIVEVE I trial. J Women’s Health 27(3):297–304CrossRefGoogle Scholar
  8. 8.
    Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A (2018) Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 224:153–158CrossRefGoogle Scholar
  9. 9.
    Pitsouni E, Grigoriadis T, Falagas ME et al (2017) Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas 103:78CrossRefGoogle Scholar
  10. 10.
    Arunkalaivanan A, Kaur H, Onuma O (2017) Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J 28:681–685CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Juan José Escribano
    • 1
  • Pablo González-Isaza
    • 2
  • Konstantinos Tserotas
    • 3
  • Stavros Athanasiou
    • 4
  • Nicola Zerbinati
    • 5
  • Gustavo Leibaschoff
    • 6
  • Stefano Salvatore
    • 7
  • Rafael Sánchez-Borrego
    • 8
    Email author
  1. 1.Unidad Ginecoestetica, Instituto Médico LaserMadridSpain
  2. 2.División de Uroginecología y Cirugía Mínimamente Invasiva, Liga contra el CáncerHospital Universitario San JorgePereiraColombia
  3. 3.Clinica de GinecoEndocrino, Complejo Hospitalario Metropolitano Caja Seguro SocialPanamáPanama
  4. 4.Urogynaecology Unit, 1st Department of Obstetrics and Gynecology“Alexandra” Hospital, National and Kapodistrian University of AthensAthensGreece
  5. 5.Department of Dermatology, School of MedicineUniversity of InsubriaVareseItaly
  6. 6.Cosmetic Gynecology, General Secretary of the World Society of Cosmetic GynecologyDallasUSA
  7. 7.Obstetrics and Gynecology UnitVita-Salute San Raffaele University and IRCCS San Raffaele HospitalMilanItaly
  8. 8.DIATROS, Clínica de Atención a la MujerBarcelonaSpain

Personalised recommendations